Overview

Neurofibromatosis is a genetic disorder that causes tumors to form on nerve tissue. These tumors can develop anywhere in your nervous system, including your brain, spinal cord and nerves. Neurofibromatosis is usually diagnosed in childhood or early adulthood.

The tumors are usually noncancerous (benign), but sometimes can become cancerous (malignant). Symptoms are often mild. However, complications of neurofibromatosis can include hearing loss, learning impairment, heart and blood vessel (cardiovascular) problems, loss of vision, and severe pain.

Neurofibromatosis treatment focuses on encouraging healthy growth and development in children affected with the disorder and early management of complications. When neurofibromatosis causes large tumors or tumors that press on a nerve, surgery can reduce symptoms. Some people may benefit from other therapies, such as stereotactic radiosurgery or medications to control pain.

Neurofibromatosis care at Mayo Clinic

Types

Symptoms

There are three types of neurofibromatosis, each with different signs and symptoms.

Neurofibromatosis 1

Neurofibromatosis 1 (NF1) usually appears in childhood. Signs are often noticeable at birth or shortly afterward, and almost always by age 10. Signs and symptoms are often mild to moderate, but can vary in severity.

Signs and symptoms include:

  • Flat, light brown spots on the skin (cafe au lait spots). These harmless spots are common in many people. Having more than six cafe au lait spots is a strong indication of NF1. They are usually present at birth or appear during the first years of life. After early childhood, new spots stop appearing.
  • Freckling in the armpits or groin area. Freckling usually appears by ages 3 to 5. Freckles are smaller than cafe au lait spots and tend to occur in clusters in skin folds.
  • Tiny bumps on the iris of the eye (Lisch nodules). These harmless nodules can't easily be seen and don't affect vision.
  • Soft, pea-sized bumps on or under the skin (neurofibromas). These benign tumors usually develop in or under the skin, but can also grow inside the body. Sometimes, a growth will involve multiple nerves (plexiform neurofibroma). Plexiform neurofibromas, when located on the face, can cause disfigurement. Neurofibromas may increase with age.
  • Bone deformities. Abnormal bone growth and a deficiency in bone mineral density can cause bone deformities such as a curved spine (scoliosis) or bowed lower leg.
  • Tumor on the optic nerve (optic glioma). These tumors usually appear by age 3, rarely in late childhood and adolescence, and almost never in adults.
  • Learning disabilities. Impaired thinking skills are common in children with NF1 but are usually mild. Often there is a specific learning disability, such as a problem with reading or mathematics. Attention-deficit/hyperactivity disorder (ADHD) also is common.
  • Larger than average head size. Children with NF1 tend to have a larger than average head size due to increased brain volume.
  • Short stature. Children with NF1 often are below average in height.

Neurofibromatosis 2

Neurofibromatosis 2 (NF2) is much less common than NF1. Signs and symptoms of NF2 usually result from the development of benign, slow-growing tumors in both ears (acoustic neuromas), which can cause hearing loss. Also known as vestibular schwannomas, these tumors grow on the nerve that carries sound and balance information from the inner ear to the brain.

Signs and symptoms generally appear in the late teen and early adult years, and can vary in severity. Signs and symptoms can include:

  • Gradual hearing loss
  • Ringing in the ears
  • Poor balance
  • Headaches

Sometimes NF2 can lead to the growth of schwannomas in other nerves of the body, including the cranial, spinal, visual (optic) and peripheral nerves. Signs and symptoms of these schwannomas can include:

  • Numbness and weakness in the arms or legs
  • Pain
  • Balance difficulties
  • Facial drop
  • Vision problems or the development of cataracts

Schwannomatosis

This rare type of neurofibromatosis usually affects people after age 20. On average, symptoms appear between ages 25 and 30. Schwannomatosis causes tumors to develop on the cranial, spinal and peripheral nerves — but rarely on the nerve that carries sound and balance information from the inner ear to the brain. Because tumors don't usually grow on both hearing nerves, schwannomatosis doesn't cause the hearing loss experienced by people with NF2.

Symptoms of schwannomatosis include:

  • Chronic pain, which can occur anywhere in your body and can be disabling
  • Numbness or weakness in various parts of your body
  • Loss of muscle

When to see a doctor

See your doctor if you or your child develops signs or symptoms of neurofibromatosis. The tumors associated with neurofibromatosis are often benign and slow growing. So although it's important to obtain a timely diagnosis, the situation isn't an emergency.

Causes

Neurofibromatosis is caused by genetic defects (mutations) that either are passed on by a parent or occur spontaneously at conception. The specific genes involved depend on the type of neurofibromatosis:

  • NF1. The NF1 gene is located on chromosome 17. This gene produces a protein called neurofibromin that helps regulate cell growth. The mutated gene causes a loss of neurofibromin, which allows cells to grow uncontrolled.
  • NF2. The NF2 gene is located on chromosome 22, and produces a protein called merlin (also called schwannomin), which suppresses tumors. The mutated gene causes a loss of merlin, leading to uncontrolled cell growth.
  • Schwannomatosis. So far, two genes are known to cause schwannomatosis. Mutations of the genes SMARCB1 and LZTR1, which suppress tumors, are associated with this type of neurofibromatosis.

Risk factors

The biggest risk factor for neurofibromatosis is a family history of the disorder. About half of people with NF1 and NF2 inherited the disease from the affected parent. People with NF1 and NF2 that don't have affected relatives likely have a new gene mutation.

NF1 and NF2 are both autosomal dominant disorders, which means that any child of a parent with the disorder has a 50 percent chance of inheriting the genetic mutation.

The inheritance pattern for schwannomatosis is less clear. Researchers currently estimate that the risk of inheriting schwannomatosis from an affected parent is about 15 percent.

Complications

Complications of neurofibromatosis vary, even within the same family. Generally, complications result from tumor growth distorting nerve tissue or pressing on internal organs.

NF1 complications

Complications of NF1 include:

  • Neurological problems. Learning and thinking difficulties are the most common neurological problems associated with NF1. Uncommon complications include epilepsy and the buildup of excess fluid in the brain.
  • Concerns with appearance. Visible signs of neurofibromatosis — such as extensive cafe au lait spots, many neurofibromas in the facial area or large neurofibromas — can cause anxiety and emotional distress, even if they're not medically serious.
  • Skeletal problems. Some children have abnormally formed bones, which can result in bowing of the legs and fractures that sometimes don't heal. NF1 can cause curvature of the spine (scoliosis) that may need bracing or surgery. NF1 is also associated with decreased bone mineral density, which increases the risk of weak bones (osteoporosis).
  • Vision problems. Sometimes a tumor develops in children on the optic nerve (optic glioma), which can affect vision.
  • Problems during times of hormonal change. Hormonal changes associated with puberty or pregnancy might cause an increase in neurofibromas. Most women with NF1 have healthy pregnancies but will likely need monitoring by an obstetrician familiar with the disorder.
  • Cardiovascular problems. People with NF1 have an increased risk of high blood pressure and may develop blood vessel abnormalities.
  • Breathing problems. Rarely, plexiform neurofibromas can put pressure on the airway.
  • Cancer. An estimated 3 to 5 percent of people with NF1 develop cancerous tumors. These usually arise from neurofibromas under the skin or from plexiform neurofibromas. People with NF1 also have a higher risk of other forms of cancer, such as breast cancer, leukemia, colorectal cancer, brain tumors and some types of soft tissue cancer. Women with NF1 should start screening for breast cancer at an earlier age than the general population.
  • Benign adrenal gland tumor (pheochromocytoma). This noncancerous tumor secretes hormones that raise your blood pressure. Surgery is usually needed to remove the pheochromocytoma.

NF2 complications

Complications of NF2 include:

  • Partial or total deafness
  • Facial nerve damage
  • Vision problems
  • Small benign skin tumors (skin schwannomas)
  • Weakness or numbness in the extremities
  • Multiple benign brain tumors or spinal tumors (meningiomas) requiring frequent surgeries

Schwannomatosis complications

The pain caused by schwannomatosis can be debilitating and may require surgical treatment or management by a pain specialist.

Neurofibromatosis care at Mayo Clinic

Dec. 04, 2018
References
  1. Ferri FF. Neurofibromatosis. In: Ferri's Clinical Advisor 2019. Philadelphia, Pa.: Elsevier; 2019. https://www.clinicalkey.com. Accessed Sept. 17, 2018.
  2. Neurofibromatosis fact sheet. National Institute of Neurological Disorders and Stroke. https://www.ninds.nih.gov/Disorders/Patient-Caregiver-Education/Fact-Sheets/Neurofibromatosis-Fact-Sheet. Accessed Sept. 17, 2018.
  3. Korf BR. Neurofibromatosis type 1 (NF1): Pathogenesis, clinical features, and diagnosis. https://www.uptodate.com/contents/search. Accessed Sept. 17, 2018.
  4. Evans DG. Neurofibromatosis type 2. https://www.uptodate.com/contents/search. Accessed Sept. 17, 2018.
  5. Yohay K, et al. Schwannomatosis. https://www.uptodate.com/home. Accessed Sept. 17, 2018.
  6. Korf BR. Neurofibromatosis type 1 (NF1): Management and prognosis. https://www.uptodate.com/contents/search. Accessed Sept. 17, 2018.
  7. Kinori M, et al. Ophthalmic manifestations in neurofibromatosis type 1. Survey of Ophthalmology. 2018;63:518.
  8. Chung LK, et al. A systemic review of radiosurgery versus surgery for neurofibromatosis type 2 vestibular schwannomas. World Neurosurgery. 2018;109:47.
  9. AskMayoExpert. Neurofibromatoses. Rochester, Minn.: Mayo Foundation for Medical Education and Research; 2018.
  10. Neurofibromatosis. American Association of Neurological Surgeons. https://www.aans.org/en/Patients/Neurosurgical-Conditions-and-Treatments/Neurofibromatosis. Accessed Sept. 21, 2018.
  11. What is acoustic neuroma? Acoustic Neuroma Association. https://www.anausa.org/learn-about-acoustic-neuroma/what-is-acoustic-neuroma#anatomy-of-an-acoustic-neuroma. Accessed Sept. 24, 2018.
  12. Flint PW, et al., eds. Stereotactic radiation treatment of benign tumors of the cranial base. In: Cummings Otolaryngology: Head & Neck Surgery. 6th ed. Philadelphia, Pa.: Saunders Elsevier; 2015. https://www.clinicalkey.com. Accessed Sept. 17, 2018.
  13. Daroff RB, et al. Neurocutaneous syndromes. In: Bradley's Neurology in Clinical Practice. 7th ed. Philadelphia, Pa.: Saunders Elsevier; 2016. https://www.clinicalkey.com. Accessed Sept. 24, 2018.
  14. Bope ET, et al. Pheochromocytoma. In: Conn's Current Therapy 2018. Philadelphia, Pa.: Elsevier; 2018. https://www.clinicalkey.com. Accessed Oct. 24, 2018.
  15. Walker JA, et al. Emerging therapeutic targets for neurofibromatosis type 1. Expert Opinion on Therapeutic Targets. 2018;22:419.
  16. Brown AY. Allscripts EPSi. Mayo Clinic, Rochester, Minn. Sept. 25, 2018.
  17. Furman JM, et al. Evaluation of the patient with vertigo. https://www.uptodate.com/contents/search. Accessed Sept. 28, 2018.
  18. National Cancer Institute. Brain stem auditory evoked response test. NCI Dictionary of Cancer Terms. https://www.cancer.gov/publications/dictionaries/cancer-terms/def/brain-stem-auditory-evoked-response-test. Accessed Sept. 28, 2018.
  19. Howell SJ, et al. Increased risk of breast cancer in neurofibromatosis type 1: Current insights. Breast Cancer. 2017;9:531.
  20. Babovic-Vuksanovic D (expert opinion). Mayo Clinic, Rochester, Minn. Oct. 8, 2018.